Evidence map›Paper›PMID 39922945›Full record

ArticleScientific reports2025

Severe COVID-19 disease is associated with genetic factors affecting plasma ACE2 receptor and CRP concentrations.

Verena Vogi, David Haschka, Lukas Forer, Simon Schwendinger, Verena Petzer, Stefan Coassin, Ivan Tancevski, Thomas Sonnweber, Judith Löffler-Ragg, Elisabeth Puchhammer-Stöckl and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Verena Vogi *Institute of Human Genetics, Medical University Innsbruck, Innsbruck, 6020, Austria.
David Haschka *Department of Internal Medicine II (Infectious Diseases, Immunology, Pneumology and Rheumatology), Medical University Innsbruck, Innsbruck, 6020, Austria.
Lukas ForerInstitute of Genetic Epidemiology, Medical University Innsbruck, Innsbruck, 6020, Austria.
Simon SchwendingerInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, 6020, Austria.
Verena PetzerDepartment of Internal Medicine V (Hematology and Internistic Oncology), Medical University Innsbruck, Innsbruck, 6020, Austria.
Stefan CoassinInstitute of Genetic Epidemiology, Medical University Innsbruck, Innsbruck, 6020, Austria.
Ivan TancevskiDepartment of Internal Medicine II (Infectious Diseases, Immunology, Pneumology and Rheumatology), Medical University Innsbruck, Innsbruck, 6020, Austria.
Thomas SonnweberDepartment of Internal Medicine II (Infectious Diseases, Immunology, Pneumology and Rheumatology), Medical University Innsbruck, Innsbruck, 6020, Austria.
Judith Löffler-RaggDepartment of Internal Medicine II (Infectious Diseases, Immunology, Pneumology and Rheumatology), Medical University Innsbruck, Innsbruck, 6020, Austria.
Elisabeth Puchhammer-StöcklDepartment of Virology, Medical University Vienna, Vienna, 1090, Austria.
Marianne GraningerDepartment of Virology, Medical University Vienna, Vienna, 1090, Austria.
Dominik WolfDepartment of Internal Medicine V (Hematology and Internistic Oncology), Medical University Innsbruck, Innsbruck, 6020, Austria.
Florian KronenbergInstitute of Genetic Epidemiology, Medical University Innsbruck, Innsbruck, 6020, Austria.
Johannes ZschockeInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, 6020, Austria.
Emina Jukic *Institute of Human Genetics, Medical University Innsbruck, Innsbruck, 6020, Austria. emina.jukic@i-med.ac.at.
Günter Weiss *Department of Internal Medicine II (Infectious Diseases, Immunology, Pneumology and Rheumatology), Medical University Innsbruck, Innsbruck, 6020, Austria. guenter.weiss@i-med.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hyperinflammatory state with highly elevated concentrations of inflammatory biomarkers such as C-reactive protein (CRP) is a characteristic feature of severe coronavirus disease 2019 (COVID-19). To examine a potential role of common genetic factors that may influence COVID-19 outcomes, we investigated whether individuals with a polygenic predisposition for a pro-inflammatory response (in the form of Polygenic Scores) are more likely to develop severe COVID-19. The innovative approach of polygenic scores to investigate genetic factors in COVID-19 severity should provide a comprehensive approach beyond single-gene studies. In our cohort of 156 patients of European ancestry, two overlapping Polygenic Scores (PGS) predicting a genetic predisposition to basal CRP concentrations were significantly different between non-severe and severe COVID-19 cases and were associated with less severe COVID-19 outcomes. Furthermore, specific single nucleotide polymorphisms (SNPs) that contribute to either of the two Polygenic Scores predicting basal CRP levels are associated with different traits that represent risk factors for COVID-19 disease initiation (ACE2 receptor, viral replication) and progression (CRP). We suggest that genetically determined enforced CRP formation may contribute to strengthening of innate immune responses and better initial pathogen control thereby reducing the risk of subsequent hyperinflammation and adverse course of COVID-19.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19C-Reactive ProteinAdultAgedBiomarkersFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMultifactorial InheritancePolymorphism, Single NucleotideRisk FactorsSARS-CoV-2Severity of Illness IndexACE2 protein, humanAngiotensin-Converting Enzyme 2BiomarkersC-Reactive Protein

Identifiers

PMID39922945
PMCPMC11807156

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.